1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Cachet Pharmaceutical Co., Ltd. Class A

Cachet Pharmaceutical Co., Ltd. Class A

SSZSE:002462
11.61
CNY
+0.11
(+0.96%)
0.38EPS
26.57P/E
3.13BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14.7
23.21
34.13
43.77
56.71
71.81
84.98
79.82
87.62
90.07
103.16
82.02
66.62
62.9
Basic EPS, GAAP
0.54
0.95
0.72
0.89
1.05
1.31
1.44
1.09
1.21
1.02
0.86
0.54
0.38
0.4
Free Cash Flow per Basic Share
-1.39
-3.41
-1.57
0.31
-1.57
-1.25
0.12
2.94
2.28
-1.21
4.8
0.56
4.67
- -
Dividend per Share
0.14
0.45
0.44
0.52
0.48
0.89
0.96
0.99
0.83
0.97
0.74
0.57
0.37
0.06
Book Value per Share
4.94
5.36
5.96
7.91
8.81
9.97
11.74
12.44
13.32
13.98
14.54
14.71
14.92
15.22
Tangible Book Value per Share
4.39
3.31
3.82
5.86
6.05
7.23
9.41
10.36
11.27
12.09
12.78
13.27
13.64
13.94
Basic Weighted Avg Shares
241
240
240
251
251
250
261
291
292
291
291
293
293
292
Sales/Revenue/Turnover
3,544
5,572
8,200
10,972
14,239
17,960
22,187
23,256
25,626
26,220
29,996
24,019
19,525
18,366
Operating Margin (%)
3.99
5.64
5.98
5.78
5.21
5.45
5.02
5.16
4.05
3.61
3.02
2.84
3.67
3.51
Depreciation Expense
17
22
25
28
30
32
81
176
201
227
202
127
87
- -
Net Income, GAAP
130
228
173
223
264
328
376
318
354
297
250
158
111
118
Effective Tax Rate (%)
24.52
25.36
25.23
25.76
25.38
26.36
25.66
27.43
26.95
27.38
32.19
42.07
63.43
61.43
Profit Margin (%)
3.67
4.09
2.11
2.03
1.85
1.82
1.69
1.37
1.38
1.13
0.83
0.66
0.57
0.64
Working Capital
719
741
1,197
1,917
2,759
3,317
3,572
3,971
4,263
4,581
4,781
5,091
5,068
5,178
LT Debt
- -
- -
- -
6
746
746
193
176
229
209
176
130
104
94
Total Equity
1,303
1,675
2,202
2,935
3,197
3,733
4,923
5,324
5,657
5,922
6,092
5,993
5,876
5,964
Return on Invested Capital (%)
9.66
14.55
9.24
9.68
8.82
8.72
8.43
6.76
6.5
4.8
3.78
3.57
1.31
1.31
Return on Capital (%)
9.04
8.34
3.21
2.31
2.63
3.44
2.99
1.98
2.41
2.64
2.33
0.79
1.83
1.51
Return on Common Equity (%)
11.41
18.44
12.73
13.08
12.59
13.93
12.7
9
9.42
7.46
6.01
3.71
2.58
2.68

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,737
1,698
1,455
LT Borrowings
- -
- -
- -
LT Finance Leases
104
96
94
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
292
292
292
Market Capitalization
4,189
4,201
3,130

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
11,835
11,044
10,735
Cash, Cash Equivalents & STI
2,564
2,281
2,621
Accounts Receivable, Net
5,890
5,602
5,444
Inventories
2,465
2,478
2,102
Total Current Liabilities
6,767
5,927
5,557
Payables & Accruals
- -
- -
- -
ST Debt
1,737
1,698
1,455
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.92%
2.05%
-1.96%
Free Cash Flow
181.08%
-5.93%
730.29%
Net Income, GAAP
-1.61%
-17.36%
-29.57%
Sales/Revenue/Turnover
10.63%
-2.35%
-18.71%
Total Cash Common Dividend
4.79%
-16.13%
-35.03%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,443
5,396
5,651
5,529
24,019
2025
4,678
5,021
- -
5,067
19,525
2026
3,972
4,306
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.26
0.32
0.22
-0.25
0.54
2025
0.16
0.21
- -
-0.1
0.38
2026
0.13
0.17
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.33
0.19
-0.06
0.57
2025
0.12
0.2
- -
-0.2
0.37
2026
0.02
0.04
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yibin Huang
Full Time Employees
1,741
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building 1 Beijing BE China 100195
IPO Date
Aug 3, 2010
Website
cachet.com.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Cachet Pharmaceutical Co., Ltd. Cachet Pharmaceutical Co., Ltd. (002462.SZ) is a China-based company primarily engaged in pharmaceutical wholesale, retail, and distribution. The company provides pharmaceutical sales including biochemical drugs and traditional Chinese medicines; medical equipment and device sales; pharmaceutical logistics and chain retail services; and health care products. Founded in 1997 and headquartered in Beijing, it operates principally within China and listed on the Shenzhen Stock Exchange in 2010, entering the China Everbright Group China Everbright Limited system in 2018 as the main platform for its health business sector. In recent developments, the company approved a final cash dividend on A shares for the year 2024, payable on 30 June 2025, reflecting ongoing financial stability amid its focus on innovation, technology-driven reforms, and expansion in drug and medical device distribution.